stockportfolio.pro
Aclaris Therapeutics, Inc. (ACRS)
Healthcare · Biotechnology · NasdaqGS
Aclaris Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.68M | $6.15M | $4.23M | $6.48M | $6.76M | $29.75M | $31.25M | $18.72M | $7.83M |
| Gross profit | — | $476,000 | $3.24M | $172,000 | $1.35M | $2.05M | $17.79M | $13.17M | $3.26M | $542,000 |
| Net income | $-48.08M | $-68.52M | $-132.74M | $-161.35M | $-51.02M | $-90.86M | $-86.91M | $-88.48M | $-132.06M | $-64.92M |
| Net margin | — | -4071.5% | -2158.0% | -3817.2% | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
Source: Aclaris Therapeutics, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Aclaris Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ACRS in your portfolio →
Aclaris Therapeutics, Inc. financial history by metric
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics, Inc. — frequently asked questions
What is Aclaris Therapeutics, Inc.'s revenue?
Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.83M for fiscal year 2025, down 58.2% from the prior year, according to its SEC filings.
Is Aclaris Therapeutics, Inc. profitable?
No — ACRS reported a net loss of $-64.92M in fiscal 2025.
What is ACRS's P/E ratio?
Aclaris Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Aclaris Therapeutics, Inc. growing?
ACRS's revenue grew at roughly 3.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Aclaris Therapeutics, Inc. have?
As of fiscal year 2025, ACRS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Aclaris Therapeutics, Inc.'s gross margin?
ACRS's gross margin was 6.9% in fiscal 2025 — gross profit of $542,000 on revenue of $7.83M.
What is Aclaris Therapeutics, Inc.'s market cap?
Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of about $599.16M, based on the latest data in our nightly-refreshed cache.
When does Aclaris Therapeutics, Inc.'s fiscal year end?
ACRS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Aclaris Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.